- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20
U.S. Pharmaceuticals & Biotech Strong Past Earnings Growth, P/E Ratio Below 20
Results
4
A list of companies that grew earnings by 20% and are trading on less than 20 times earnings. All with a debt to equity ratio below 1.
4 companies
Johnson & Johnson
Market Cap: US$366.8b
Engages in the research and development, manufacture, and sale of various products in the healthcare field worldwide.
JNJ
US$153.58
7D
0.6%
1Y
5.7%
Biogen
Market Cap: US$18.7b
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally.
BIIB
US$132.75
7D
5.1%
1Y
-39.7%
Royalty Pharma
Market Cap: US$18.3b
Operates as a buyer of biopharmaceutical royalties and a funder of innovation in the biopharmaceutical industry in the United States.
RPRX
US$32.64
7D
1.0%
1Y
23.7%
DermTech
Market Cap: US$35.0
A molecular diagnostic company, engages in the development and marketing of novel non-invasive genomics tests to aid in the diagnosis and management of melanoma in the United States.
DMTK.Q
US$0.000001
7D
0%
1Y
-100.0%